Aberrant MicroRNAs in pancreatic cancer: Researches and clinical implications

Gastroenterology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Sun, Tao ^a   Kong, Xiangyu ^a   Du, Yiqi ^a   Li, Zhaoshen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TROPOMYOSIN; GELATINASE A; METALLOPROTEINASE; MICRORNA; MICRORNA 10A; MICRORNA 146A; MICRORNA 148A; MICRORNA 148B; MICRORNA 155; MICRORNA 15B; MICRORNA 181; MICRORNA 196A; MICRORNA 198; MICRORNA 200C; MICRORNA 20A; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 373; MICRORNA 375; MICRORNA 424 5P; MICRORNA 96; MUCIN 4; PLATELET DERIVED GROWTH FACTOR; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; VASCULOTROPIN;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; DOWN REGULATION; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; HUMAN; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS ISLET CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; RADIOSENSITIVITY; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84901807877     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2014/386561     Document Type: Review

References (104)

1. Yang L., Yang H., Li J., ppENK gene methylation status in the development of pancreatic carcinoma. Gastroenterology Research and Practice 2013 2013 8 130927 10.1155/2013/130927
2. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 2013 63 1 11 30
3. Ambros V., The functions of animal microRNAs. Nature 2004 431 7006 350 355 2-s2.0-4644309196 10.1038/nature02871 (Pubitemid 39265675)
4. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
5. Du Y., Liu M., Gao J., Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Cancer Biother Radiopharm 2013 28 5 361 369 10.1089/cbr.2012.1389
6. Li M., Marin-Muller C., Bharadwaj U., Chow K.-H., Yao Q., Chen C., MicroRNAs: control and loss of control in human physiology and disease. World Journal of Surgery 2009 33 4 667 684 2-s2.0-62549098152 10.1007/s00268-008-9836- x
7. Singh P. K., Brand R. E., Mehla K., MicroRNAs in pancreatic cancer metabolism. Nature Reviews Gastroenterology and Hepatology 2012 9 6 334 344 10.1038/nrgastro.2012.63
8. Zhang L., Jamaluddin M. S., Weakley S. M., Yao Q., Chen C., Roles and mechanisms of MicroRNAs in pancreatic cancer. World Journal of Surgery 2011 35 8 1725 1731 2-s2.0-80051572484 10.1007/s00268-010-0952-z
9. Calin G. A., Dumitru C. D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C. M., Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 2002 99 24 15524 15529 2-s2.0-18744396337 10.1073/pnas.242606799 (Pubitemid 35403967)
10. Di Leva G., Croce C. M., miRNA profiling of cancer. Current Opinion in Genetics & Development 2013 23 1 3 11 10.1016/j.gde.2013.01.004
11. Wang Z., Wu J., Zhang G., Associations of miR-499 and miR-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterology Research and Practice 2013 2013 8 719202 10.1155/2013/719202
12. Croce C. M., Calin G. A., miRNAs, cancer, and stem cell division. Cell 2005 122 1 6 7 2-s2.0-22144461002 10.1016/j.cell.2005.06.036 (Pubitemid 40977933)
13. Esquela-Kerscher A., Slack F. J., Oncomirs-MicroRNAs with a role in cancer. Nature Reviews Cancer 2006 6 4 259 269 2-s2.0-33645294070 10.1038/nrc1840
14. Meltzer P. S., Cancer genomics: small RNAs with big impacts. Nature 2005 435 7043 745 746 2-s2.0-20444436381 10.1038/435745a (Pubitemid 40839710)
15. Lu J., Getz G., Miska E. A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B. L., Mak R. H., Ferrando A. A., Downing J. R., Jacks T., Horvitz H. R., Golub T. R., MicroRNA expression profiles classify human cancers. Nature 2005 435 7043 834 838 2-s2.0-20444460289 10.1038/nature03702 (Pubitemid 40839735)
16. Nelson K. M., Weiss G. J., MicroRNAs and cancer: past, present, and potential future. Molecular Cancer Therapeutics 2008 7 12 3655 3660 2-s2.0-57749086300 10.1158/1535-7163.MCT-08-0586
17. Baker M. B., Bao G., Searles C. D., In vitro quantification of specific microRNA using molecular beacons. Nucleic Acids Research 2012 40 2 e13 2-s2.0-84855867686 10.1093/nar/gkr1016
18. Sun Y., Gregory K. J., Chen N. G., Rapid and direct microRNA quantification by an enzymatic luminescence assay. Analytical Biochemistry 2012 429 1 11 17
19. Wang J., Yi X., Tang H., Direct quantification of microRNA at low picomolar level in sera of glioma patients using a competitive hybridization followed by amplified voltammetric detection. Analytical Chemistry 2012 84 15 6400 6406 10.1021/ac203368h
20. Poy M. N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X., MacDonald P. E., Pfeffer S., Tuschl T., Rajewsky N., Rorsman P., Stoffel M., A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004 432 7014 226 230 2-s2.0-9144270691 10.1038/nature03076 (Pubitemid 39545853)
21. Jiang J., Lee E. J., Gusev Y., Schmittgen T. D., Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Research 2005 33 17 5394 5403 2-s2.0-27244433702 10.1093/nar/gki863 (Pubitemid 41548806)
22. Bloomston M., Frankel W. L., Petrocca F., Volinia S., Alder H., Hagan J. P., Liu C.-G., Bhatt D., Taccioli C., Croce C. M., MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Journal of the American Medical Association 2007 297 17 1901 1908 2-s2.0-34247862190 10.1001/jama.297.17.1901 (Pubitemid 46707844)
23. Panarelli N. C., Chen Y.-T., Zhou X. K., Kitabayashi N., Yantiss R. K., MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas 2012 41 5 685 690 2-s2.0-84858976932 10.1097/MPA.0b013e318243a905
24. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J. L., Frazier M. L., Killary A. M., Sen S., MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prevention Research 2009 2 9 807 813 2-s2.0-70449700281 10.1158/1940-6207.CAPR- 09-0094
25. Dillhoff M., Liu J., Frankel W., Croce C., Bloomston M., MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. Journal of Gastrointestinal Surgery 2008 12 12 2171 2176 2-s2.0-57049090610 10.1007/s11605-008-0584-x
26. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M., MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Molecular Cancer Therapeutics 2009 8 5 1067 1074 2-s2.0-66849124564 10.1158/1535-7163.MCT-08-0592
27. Hwang J.-H., Voortman J., Giovannetti E., Steinberg S. M., Leon L. G., Kim Y.-T., Funel N., Park J. K., Kim M. A., Kang G. H., Kim S.-W., Del Chiaro M., Peters G. J., Giaccone G., Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PloS ONE 2010 5 5 2-s2.0-77956296766 10.1371/journal.pone. 0010630
28. Eun J. L., Gusev Y., Jiang J., Nuovo G. J., Lerner M. R., Frankel W. L., Morgan D. L., Postier R. G., Brackett D. J., Schmittgen T. D., Expression profiling identifies microRNA signature in pancreatic cancer. International Journal of Cancer 2007 120 5 1046 1054 2-s2.0-33846813656 10.1002/ijc.22394 (Pubitemid 46214304)
29. Su A., He S., Tian B., MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS ONE 2013 8 8 e71309 10.1371/journal.pone.0071309
30. Kawaguchi T., Komatsu S., Ichikawa D., Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. British Journal of Cancer 2013 108 2 361 369 10.1038/bjc.2012.546
31. Liu Q., Chen J., Wang J., Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Molecular Carcinogenesis 2013 10.1002/mc.22023
32. Greither T., Grochola L. F., Udelnow A., Lautenschläger C., Würl P., Taubert H., Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. International Journal of Cancer 2010 126 1 73 80 2-s2.0-73449134501 10.1002/ijc.24687
33. Szafranska A. E., Davison T. S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S. A., MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007 26 30 4442 4452 2-s2.0-34248200155 10.1038/sj.onc.1210228 (Pubitemid 47014466)
34. Zhang Y., Li M., Wang H., Fisher W. E., Lin P. H., Yao Q., Chen C., Profiling of 95 MicroRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World Journal of Surgery 2009 33 4 698 709 2-s2.0-62549109089 10.1007/s00268-008-9833-0
35. Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., Zhang Z., Zhu J., Jing Q., Qin Y., Li Z., Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: MiR-196a could be a potential marker for poor prognosis. Digestive Diseases and Sciences 2011 56 2 602 609 2-s2.0-79952441602 10.1007/s10620-010-1285-3
36. Szafranska A. E., Doleshal M., Edmunds H. S., Gordon S., Luttges J., Munding J. B., Barth R. J. Jr., Gutmann E. J., Suriawinata A. A., Pipas J. M., Tannapfel A., Korc M., Hahn S. A., Labourier E., Tsongalis G. J., Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clinical Chemistry 2008 54 10 1716 1724 2-s2.0-54049115957 10.1373/clinchem.2008.109603
37. Wu K., Hu G., He X., MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathology & Oncology Research 2013 19 4 739 748 10.1007/s12253-013-9637-x
38. Ohuchida K., Mizumoto K., Lin C., Yamaguchi H., Ohtsuka T., Sato N., Toma H., Nakamura M., Nagai E., Hashizume M., Tanaka M., MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Annals of Surgical Oncology 2012 19 7 2394 2402 2-s2.0-84857871152 10.1245/s10434-012-2252-3
39. Zhang Y., Yang J., Cui X., A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Molecular Medicine 2013 5 9 1322 1334
40. Ma Y., Yu S., Zhao W., Lu Z., Chen J., MiR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Letters 2010 298 2 150 158 2-s2.0-77957948990 10.1016/j.canlet.2010.06. 012
41. Takikawa T., Masamune A., Hamada S., miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochemical and Biophysical Research Communications 2013 437 3 433 439 10.1016/j.bbrc.2013.06.097
42. Ho A. S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.-T., Koong A. C., Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Translational Oncology 2010 3 2 109 113 2-s2.0-77952111316 10.1593/tlo.09256
43. Zhang R., Li M., Zang W., MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour Biology 2014 35 1 837 844 10.1007/s13277-013-1115-2
44. Hanoun N., Delpu Y., Suriawinata A. A., Bournet B., Bureau C., Selves J., Tsongalis G. J., Dufresne M., Buscail L., Cordelier P., Torrisani J., The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clinical Chemistry 2010 56 7 1107 1118 2-s2.0-77954357983 10.1373/clinchem.2010.144709
45. Marin-Muller C., Li D., Bharadwaj U., A tumorigenic factor interactome connected through tumor suppressor MicroRNA-198 in human pancreatic cancer. Clinical Cancer Research 2013 19 21 5901 5913
46. Li Y., VandenBoom T. G. II, Wang Z., Kong D., Ali S., Philip P. A., Sarkar F. H., miR-146a suppresses invasion of pancreatic cancer cells. Cancer Research 2010 70 4 1486 1495 2-s2.0-76749152907 10.1158/0008-5472.CAN-09-2792
47. Yan H., Wu J., Liu W., Zuo Y., Chen S., Zhang S., Zeng M., Huang W., MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells. Human Gene Therapy 2010 21 12 1723 1734 2-s2.0-78650096337 10.1089/hum.2010.061
48. Yu S., Lu Z., Liu C., Meng Y., Ma Y., Zhao W., Liu J., Yu J., Chen J., miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Research 2010 70 14 6015 6025 2-s2.0-77955033963 10.1158/0008-5472.CAN-09-4531
49. Yu J., Ohuchida K., Mizumoto K., Sato N., Kayashima T., Fujita H., Nakata K., Tanaka M., MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Molecular Cancer 2010 9, article 169 2-s2.0-77953950190 10.1186/1476-4598-9-169
50. Radhakrishnan P., Mohr A. M., Grandgenett P. M., MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. PLoS ONE 2013 8 10 e73356 10.1371/journal.pone.0073356
51. Torrisani J., Bournet B., Du Rieu M. C., Bouisson M., Souque A., Escourrou J., Buscail L., Cordelier P., Let-7 microRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Human Gene Therapy 2009 20 8 831 844 2-s2.0-68949213672 10.1089/hum.2008.134
52. Xu Q., Zhang T.-P., Zhao Y.-P., Advances in early diagnosis and therapy of pancreatic cancer. Hepatobiliary and Pancreatic Diseases International 2011 10 2 128 135 2-s2.0-79953908354
53. Sahani D. V., Shah Z. K., Catalano O. A., Boland G. W., Brugge W. R., Radiology of pancreatic adenocarcinoma: current status of imaging. Journal of Gastroenterology and Hepatology 2008 23 1 23 33 2-s2.0-37249081553 10.1111/j.1440-1746.2007.05117.x (Pubitemid 350265200)
54. Albulescu R., Neagu M., Albulescu L., Tanase C., Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Review of Molecular Diagnostics 2011 11 1 101 120 2-s2.0-78650571632 10.1586/erm.10.106
55. Ansari D., Chen B.-C., Dong L., Zhou M.-T., Andersson R., Pancreatic cancer: translational research aspects and clinical implications. World Journal of Gastroenterology 2012 18 13 1417 1424 2-s2.0-84859336668 10.3748/wjg.v18.i13. 1417
56. Bauer A. S., Keller A., Costello E., Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS ONE 2012 7 4 e34151 10.1371/journal.pone.0034151
57. Calin G. A., Liu C.-G., Sevignani C., Ferracin M., Felli N., Dumitru C. D., Shimizu M., Cimmino A., Zupo S., Dono M., Dell'Aquila M. L., Alder H., Rassenti L., Kipps T. J., Bullrich F., Negrini M., Croce C. M., MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America 2004 101 32 11755 11760 2-s2.0-4143142117 10.1073/pnas.0404432101 (Pubitemid 39095368)
58. Frampton A. E., Krell J., Jacob J., Stebbing J., Jiao L. R., Castellano L., MicroRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Review of Anticancer Therapy 2011 11 12 1837 1842 2-s2.0-82355164087 10.1586/era.11.184
59. Iorio M. V., Ferracin M., Liu C.-G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Ménard S., Palazzo J. P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G. A., Querzoli P., Negrini M., Croce C. M., MicroRNA gene expression deregulation in human breast cancer. Cancer Research 2005 65 16 7065 7070 2-s2.0-23844555119 10.1158/0008-5472.CAN-05-1783 (Pubitemid 41161233)
60. Jiao L. R., Frampton A. E., Jacob J., Pellegrino L., Krell J., Giamas G., Tsim N., Vlavianos P., Cohen P., Ahmad R., Keller A., Habib N. A., Stebbing J., Castellano L., Micrornas targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE 2012 7 2 2-s2.0-84857468335 10.1371/journal.pone.0032068 e32068
61. Lawrie C. H., Gal S., Dunlop H. M., Pushkaran B., Liggins A. P., Pulford K., Banham A. H., Pezzella F., Boultwood J., Wainscoat J. S., Hatton C. S. R., Harris A. L., Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology 2008 141 5 672 675 2-s2.0-43449102192 10.1111/j.1365-2141.2008. 07077.x (Pubitemid 351667616)
62. Michael M. Z., O'Connor S. M., Van Holst Pellekaan N. G., Young G. P., James R. J., Reduced accumulation of specific MicroRNAs in colorectal neoplasia. Molecular Cancer Research 2003 1 12 882 891 2-s2.0-0142120587 (Pubitemid 37288707)
63. Piepoli A., Tavano F., Copetti M., Mazza T., Palumbo O., Panza A., Di Mola F. F., Pazienza V., Mazzoccoli G., Biscaglia G., Gentile A., Mastrodonato N., Carella M., Pellegrini F., Di Sebastiano P., Andriulli A., Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS ONE 2012 7 3 2-s2.0-84859129420 10.1371/journal.pone.0033663 e33663
64. Li A., Yu J., Kim H., Serum miR-1290 as a marker of pancreatic cancer-response. Clinical Cancer Research 2013 19 18 5252 5253
65. Goggins M., Identifying molecular markers for the early detection of pancreatic neoplasia. Seminars in Oncology 2007 34 4 303 310 2-s2.0-34547417096 10.1053/j.seminoncol.2007.05.003 (Pubitemid 47176618)
66. Gold D. V., Modrak D. E., Ying Z., Cardillo T. M., Sharkey R. M., Goldenberg D. M., New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. Journal of Clinical Oncology 2006 24 2 252 258 2-s2.0-33644815924 10.1200/JCO.2005.02.8282 (Pubitemid 46622054)
67. Liu J., Gao J., Du Y., Li Z., Ren Y., Gu J., Wang X., Gong Y., Wang W., Kong X., Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. International Journal of Cancer 2012 131 3 683 691 2-s2.0-81255144032 10.1002/ijc.26422
68. Liu R., Chen X., Du Y., Yao W., Shen L., Wang C., Hu Z., Zhuang R., Ning G., Zhang C., Yuan Y., Li Z., Zen K., Ba Y., Zhang C.-Y., Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical Chemistry 2012 58 3 610 618 2-s2.0-84857860850 10.1373/clinchem.2011.172767
69. Wang W. S., Liu L. X., Li G. P., Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prevention Research 2013 6 4 331 338 10.1158/1940-6207.CAPR-12-0307
70. Frampton A. E., Fletcher C. E., Gall T. M., Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Expert Review of Molecular Diagnostics 2013 13 5 425 430 10.1586/erm.13.31
71. Caponi S., Funel N., Frampton A. E., The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Annals of Oncology 2013 24 3 734 741 10.1093/annonc/mds513
72. Lubezky N., Loewenstein S., Ben-Haim M., MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery 2013 153 5 663 672 10.1016/j.surg.2012.11.016
73. Farrell J. J., Toste P., Wu N., Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer. The American Journal of Gastroenterology 2013 108 8 1352 1359 10.1038/ajg.2013.167
74. Ma M. Z., Kong X., Weng M. Z., Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. Journal of Experimental & Clinical Cancer Research 2013 32 1 71 10.1186/1756-9966-32-71
75. Jamieson N. B., Morran D. C., Morton J. P., Ali A., Dickson E. J., Carter C. R., Sansom O. J., Evans T. R. J., McKay C. J., Oien K. A., MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research 2012 18 2 534 545 2-s2.0-84855996930 10.1158/1078-0432.CCR-11-0679
76. Frampton A. E., Castellano L., Colombo T., MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 2014 146 1 268 277 10.1053/j.gastro.2013.10. 010
77. Lee C., He H., Jiang Y., Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Medical Oncology 2013 30 4 700 10.1007/s12032-013-0700-y
78. Zhu Z., Xu Y., Du J., Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival. Surgical Oncology 2014 109 2 89 94 10.1002/jso.23475
79. Zhao G., Zhang J. G., Shi Y., Correction: MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS ONE 2013 8 9 10.1371/annotation/497d9208-190a-44b7-ac27- aea12183f47c
80. Giovannetti E., Funel N., Peters G. J., Del Chiaro M., Erozenci L. A., Vasile E., Leon L. G., Pollina L. E., Groen A., Falcone A., Danesi R., Campani D., Verheul H. M., Boggi U., MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Research 2010 70 11 4528 4538 2-s2.0-77953169001 10.1158/0008-5472.CAN-09-4467
81. Wang P., Zhuang L., Zhang J., The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Molecular Oncology 2013 7 3 334 345
82. Hamada S., Masamune A., Miura S., miR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal 2014 26 2 179 185 10.1016/j.cellsig. 2013.11.003
83. Nagano H., Tomimaru Y., Eguchi H., MicroRNA-29a induces resistance to gemcitabine through the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. International Journal of Oncology 2013 43 4 1066 1072
84. Iwagami Y., Eguchi H., Nagano H., miR-320c regulates gemcitabine- resistance in pancreatic cancer via SMARCC1. British Journal of Cancer 2013 109 2 502 511 10.1038/bjc.2013.320
85. Yan H. J., Liu W. S., Sun W. H., miR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells. Digestive Diseases and Sciences 2012 57 12 3160 3167 10.1007/s10620-012-2400-4
86. Hu X., Macdonald D. M., Huettner P. C., Feng Z., El Naqa I. M., Schwarz J. K., Mutch D. G., Grigsby P. W., Powell S. N., Wang X., A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology 2009 114 3 457 464 2-s2.0-67651165020 10.1016/j.ygyno.2009.05.022
87. Paterson E. L., Kolesnikoff N., Gregory P. A., Bert A. G., Khew-Goodall Y., Goodall G. J., The microRNA-200 family regulates epithelial to mesenchymal transition. The Scientific World Journal 2008 8 901 904 2-s2.0-52249100806 10.1100/tsw.2008.115
88. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J. M., Wang Z., Philip P. A., Sarkar F. H., Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Research 2010 70 9 3606 3617 2-s2.0-77951745289 10.1158/0008-5472.CAN-09-4598
89. Cai B., An Y., Lv N., miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncology Reports 2013 29 5 1769 1776
90. Singh S., Chitkara D., Kumar V., miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters 2013 334 2 211 220 10.1016/j.canlet.2012.10.008
91. Chang T.-C., Wentzel E. A., Kent O. A., Ramachandran K., Mullendore M., Lee K., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C. J., Arking D., Beer M. A., Maitra A., Mendell J. T., Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular Cell 2007 26 5 745 752 2-s2.0-34249817549 10.1016/j.molcel.2007.05.010 (Pubitemid 46856245)
92. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M., Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell 2007 26 5 731 743 2-s2.0-34249822779 10.1016/j.molcel.2007.05.017 (Pubitemid 46856247)
93. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Körner H., Knyazev P., Diebold J., Hermeking H., Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008 7 16 2591 2600 2-s2.0-49749126791
94. Wang P., Zhang J., Zhang L., MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 2013 145 5 1133 1143 10.1053/j.gastro.2013.07.048
95. Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., Mello C. C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998 391 6669 806 811 2-s2.0-0032545933 10.1038/35888 (Pubitemid 28099681)
96. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 411 6836 494 498 2-s2.0-0035942736 10.1038/35078107 (Pubitemid 32494397)
97. Borel F., Konstantinova P., Jansen P. L. M., Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. Journal of Hepatology 2012 56 6 1371 1383 2-s2.0-84858422847 10.1016/j.jhep.2011.11.026
98. Morrissey D. V., Lockridge J. A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C. S., Jeffs L. B., Judge A., MacLachlan I., Polisky B., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology 2005 23 8 1002 1007 2-s2.0-23444445660 10.1038/nbt1122 (Pubitemid 41114035)
99. Fedorov Y., Anderson E. M., Birmingham A., Reynolds A., Karpilow J., Robinson K., Leake D., Marshall W. S., Khvorova A., Off-target effects by siRNA can induce toxic phenotype. RNA 2006 12 7 1188 1196 2-s2.0-33745608078 10.1261/rna.28106 (Pubitemid 43990544)
100. Tsuda N., Ishiyama S., Li Y., Ioannides C. G., Abbruzzese J. L., Chang D. Z., Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clinical Cancer Research 2006 12 21 6557 6564 2-s2.0-33751264968 10.1158/1078-0432.CCR-06-0588 (Pubitemid 44799731)
101. Tsuda N., Mine T., Ioannides C. G., Chang D. Z., Synthetic microRNA targeting glioma-associated antigen-1 protein. Methods in Molecular Biology 2009 487 435 449 2-s2.0-64549085589
102. Park J.-K., Lee E. J., Esau C., Schmittgen T. D., Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009 38 7 e190 e199 2-s2.0-70349904531 10.1097/MPA.0b013e3181ba82e1
103. Chen Z., Sangwan V., Banerjee S., miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Molecular Cancer 2013 12 1 105 10.1186/1476-4598-12-105
104. Laurila E. M., Sandström S., Rantanen L. M., Autio R., Kallioniemi A., Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes and Cancer 2012 51 6 557 568 2-s2.0-84859444423 10.1002/gcc.21941